Literature DB >> 9237626

Tyrphostin AG 494 blocks Cdk2 activation.

N Osherov1, A Levitzki.   

Abstract

We have previously shown that the EGFR kinase selective tyrphostin AG 494 fails to inhibit EGFR kinase in intact cells. Yet, AG 494 proved to inhibit EGF- or serum-induced cell proliferation (Osherov et al., J. Biol. Chem. 268 (1993) 11134-11142). In this preliminary communication we show that AG 494 as well as its close analogs AG 490 and AG 555 block Cdk2 activation. In contrast, AG 1478, a more selective EGFR kinase blocker which is also active as EGFR kinase blocker in intact cells, fails to do so. AG 494 exerts its full inhibitory activity on Cdk2 activation even when added 20 h subsequent to EGF addition when Cdk2 activation is maximal. The inhibitory activity on Cdk2 activation parallels its DNA synthesis inhibitory activity, strongly suggesting that its target is one of the molecular mechanisms involved in Cdk2 activation. AG 494 and its analogs may become useful lead compounds for the development of drugs aimed at the cell cycle machinery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237626     DOI: 10.1016/s0014-5793(97)00580-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  Immunotherapy of inflammatory demyelinating diseases of the central nervous system.

Authors:  J J Bright; S Sriram
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

3.  Characterization of phytochemicals and evaluation of anti-cancer potential of Blumea eriantha DC.

Authors:  Mohini Gore; N S Desai
Journal:  Physiol Mol Biol Plants       Date:  2014-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.